226 results about "Serotonin" patented technology

The invention discloses bifidobacterium animalis subsp. Lactis, a preparation and application of the bifidobacterium animalis subsp. Lactis in regulation of depression and intestinal flora. Belongs to the technical field of probiotic preparation. According to the application, seven strains of bacteria are separated from excrement of infants, the seven strains of bacteria comprise bifidobacterium breve, bifidobacterium animalis and bifidobacterium longum through identification, the anti-depression capacity of the seven strains of bacteria is evaluated through in-vitro experiments, a potential antidepressant bifidobacterium animalis subsp. Lactis BD1 is screened out, and further experiments prove that the antidepressant bifidobacterium animalis subsp. Lactis BD1 has the advantages that the antidepressant bifidobacterium animalis subsp. Lactis BD1 can be used for preparing the antidepressant bifidobacterium animalis subsp. Lactis BD1; the strain has the effects of improving depressive mood, intestinal bacteria unbalance and insufficient serotonin secretion in the brain caused by chronic bound stress (CRS), and compared with bifidobacterium animalis subsp. Lactis in the prior art, the strain achieves the anti-depression effect from multiple aspects, also has the effect of adjusting intestinal flora imbalance, and has the advantages of being safe and reliable. And a new treatment strategy is provided for depression and intestinal flora imbalance.

The invention belongs to the technical field of probiotics, and particularly relates to fermented lactobacillus mucus BM01 with an effect of relaxing bowel and application of the fermented lactobacillus mucus BM01. A new fermented lactobacillus mucus BM01 strain is separated from excrement of a healthy infant in Guangzhou city, Guangdong province, a zebra fish constipation model is constructed through loperamide hydrochloride, and research finds that the strain can remarkably promote intestinal tract movement, increase the content of in-vivo serotonin and inhibit the enzyme activity of dipeptidyl peptidase-4, so that the constipation of the zebra fish can be inhibited, the constipation of the zebra fish can be inhibited, and the constipation of the zebra fish can be inhibited. Therefore, the bowel relaxing effect is achieved. It is indicated that the BM01 strain can play the bowel relaxing effect through multiple mechanisms, has significant application value, can be used for research and development of drugs for treating constipation, irritable bowel syndrome and other intestinal diseases or development of health care products with the bowel relaxing effect, and can also be used as a feed additive to improve animal intestinal health and reduce disease risks. The culture benefit is improved.

The present disclosure provides compounds, pharmaceutical compositions, and methods for treating a mental disorder in a subject, which may include administering to the subject a pharmaceutical composition including a therapeutically effective amount of a non-hallucinogenic 5-HT2A receptor agonist or a pharmaceutically acceptable salt thereof, thereby treating the mental health disorder in the subject.

Provided are compounds of Formula I and Formula II, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I and Formula II are useful, for instance, in modulating dopamine and serotonin neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.

The invention discloses an application of a grape acetyl serotonin O-methyltransferase gene VvAST in induction of seedless, and a preparation method of the grape acetyl serotonin O-methyltransferase gene. Nucleotide sequences and amino acid sequences and specific applications are provided. The invention shows that overexpression of VvAST in tomato can significantly inhibit seed development and generate seedless phenotypes. Therefore, the VvAST can be used as a key molecular target for regulating and controlling the development of grape and tomato seeds, and has potential application value. Through gene editing or regulation and control of the expression level, stable and efficient seedless grape breeding is expected to be realized, and industrial development of high-quality seedless grape fruits is promoted.

There are disclosed phenethylamine compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the disclosed compounds.

The invention relates to the technical field of cell culture. The invention provides a mesenchymal stem cell culture medium without animal-derived components and application of the mesenchymal stem cell culture medium. The culture medium comprises a basic culture medium and an additive, the additives comprise FGF-2, IGF-1, glutamine, folic acid, serotonin, cholesterol, arachidonic acid, an HEPES buffer solution, sodium bicarbonate, SCF, TGF-beta, PDGF, ascorbic acid and transferrin. The mesenchymal stem cell culture medium disclosed by the invention is completely free of animal-derived components, and meets the requirements of FDA / EMA clinical-grade cell therapy products. The culture medium can support high-density amplification of mesenchymal stem cells, the activity of passage cells is effectively improved, and the amplification time is shortened. The method has remarkable significance in improving the amplification efficiency of the mesenchymal stem cells and promoting and applying factory growth.

The present invention aims to provide a method for evaluating the serotonin reuptake inhibitory effect of a composition containing valerian extract. [Solution] The present invention provides a method for evaluating antidepressant effects, which involves quantitatively analyzing one or more components contained in at least a part of a plant of the genus Valerian or a processed product thereof, and evaluating the antidepressant effect of the test substance by referring to the results of the quantitative analysis and criteria for antidepressant effect.

The present invention relates to a novel Noradrenergic and Specific Serotonergic Anxiolytic and Antidepressant (NaSSA) and a method for the production and use thereof for treating mental disorders.The subject of this invention is a novel noradrenergic and specific serotonergic drug for the treatment of mental disorders in humans, which is 2,8-dimethyl-5-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole hydrochloride (A·HCl), a polymorphous modification thereof, and methods for the production and use thereof.

The present invention provides a compound which has a serotonin 5-HT2A receptor inverse agonist effect, a pharmaceutically acceptable salt thereof, and a composition which is for serotonin 5-HT2A receptor inverse agonism and which contains the compound or the salt. Provided is a composition which is for serotonin 5-HT2A receptor inverse agonism and which contains a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (I) (In formula (I), R1 is a substituted or unsubstituted aromatic heterocyclic group or the like, each R2 is independently a hydrogen atom or the like, each R3 is independently a hydrogen atom or the like, n is 1 or 2, R4 is a substituted or unsubstituted non-aromatic nitrogen-containing heterocyclic group, L is -NR8- or the like, R8 is a hydrogen atom or the like, each R5 is independently a hydrogen atom or the like, each R6 is independently a hydrogen atom or the like, p is 1 or 2, and R7 is a group represented by the other formula shown.) (In the other formula shown, R9 is substituted or unsubstituted alkyloxy or the like, R10 is a hydrogen atom or the like, R11 is halogen or the like, and m is 0 or 1.)

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a serotonin receptor, such as serotonin receptor 5HT1a, 5HT1b, 5HT1d, 5HT1e, 5HT1f, 5HT2a, 5HT2b, 5HT2c, 5HT3, 5HT4, 5HT6, or 5HT7.

Provided are a compound having serotonin 5-HT2A receptor antagonism and / or inverse agonism, a pharmaceutically acceptable salt thereof, and a composition for serotonin 5-HT2A receptor antagonism and / or inverse agonism comprising them.A compound represented by Formula (I):wherein R1 is substituted or unsubstituted aromatic heterocyclyl or the like; R2 is each independently a hydrogen atom or the like; R3 is each independently a hydrogen atom or the like; n is 1 or the like; a combination of (L1, L2) is (NH, N) or the like; R4 is a group represented by Formula:wherein p and q are each independently 2 or the like; Ra is substituted or unsubstituted alkyl or the like; Xb is each independently CRbRb′; Rb is each independently a hydrogen atom or the like; Rb′ is each independently a hydrogen atom or the like; Xc is each independently CRcRc′; Rc is each independently a hydrogen atom or the like; Rc′ is each independently a hydrogen atom or the like; Xd is CRd or the like; and Rd is a hydrogen atom or the like; R5 and R6 are each independently a hydrogen atom or the like; and R7 is a group represented by Formula:wherein A is CR11 or the like; R9 is substituted or unsubstituted alkyloxy or the like; R10 is a hydrogen atom or the like; and R11 is each independently a hydrogen atom or the like; or a pharmaceutically acceptable salt thereof.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complementary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a serotonin receptor, such as serotonin receptor 5HT1a, 5HT1b, 5HT1d, 5HT1e, 5HT1f, 5HT2a, 5HT2b, 5HT2c, 5HT3, 5HT4, 5HT6, or 5HT7.

The present invention discloses a neurotransmitter detection method based on an integrated derivatization and solid phase extraction continuous reaction platform; the neurotransmitters include at least: Class A neurotransmitters have no primary amine groups, hydroxyl groups, and carboxyl groups, and have secondary amine groups or quaternary ammonium groups; Class B neurotransmitters contain at least one of primary amine groups, hydroxyl groups, and carboxyl groups; before detection, an aqueous phase derivatization system containing benzoyl chloride is used to derivatize the neurotransmitters in the sample, and an aqueous formic acid solution is added to the obtained supernatant to mix and centrifuge, and the obtained supernatant is subjected to LC-MS analysis after solid phase extraction. The present invention forms an integrated derivatization and solid phase extraction continuous reaction platform through process design, and realizes high-sensitivity simultaneous detection of at least two types of neurotransmitters. Melatonin, serotonin, histamine, and dopamine are detected simultaneously with high sensitivity, and the detection sensitivity is 1pg / mL for melatonin, 1ng / mL for serotonin, 0.03ng / mL for histamine, and 10pg / mL for dopamine.

Provided is a mutated promoter sequence. The mutated promoter sequence has a base mutation relative to a parent promoter. The parent promoter is a promoter derived from a tomato SlTDC1 gene. The mutated promoter sequence results in an increase in the content of serotonin in tomato fruits, possessing broad application prospects.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complementary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a serotonin receptor, such as serotonin receptor 5HT1a, 5HT1b, 5HT1d, 5HT1e, 5HT1f, 5HT2a, 5HT2b, 5HT2c, 5HT3, 5HT4, 5HT6, or 5HT7.

The present invention provides a polypeptide NR6 having a dual function of regulating the activity of DBH and DDC enzymes and its application, belonging to the technical field of functional polypeptides. The present invention provides a polypeptide NR6 for the research of interfering small peptides that can target lipopolysaccharide binding protein and dopamine β-hydroxylase and aromatic L-amino acid decarboxylase, which has not yet been seen, and has the function of promoting the activity of dopamine β-hydroxylase and aromatic L-amino acid decarboxylase, thereby promoting the release of dopamine, norepinephrine, epinephrine, serotonin and melatonin in the body, and has anti-inflammatory, anti-depressant, memory recovery, sleep improvement, mental recovery and other functions. In addition, NR6 and its series of small peptides can penetrate the blood-brain barrier and have the advantages of small molecular weight and high stability, which are conducive to commercial application.

This invention discloses the application of ethinylestradiol and drospirenone in the preparation of drugs for treating post-traumatic stress disorder (PTSD). Ethinylestradiol, as an estrogen receptor agonist, regulates the hypothalamic-pituitary-gonadal axis and is used to treat female hypogonadism, menopausal syndrome, and advanced breast cancer, often in combination with progestins as oral contraceptives. The use of drospirenone and ethinylestradiol tablets (II) after induced abortion can shorten vaginal bleeding time, promote endometrial repair, and reduce the incidence of postoperative complications and repeat miscarriages. This invention has found that ethinylestradiol and drospirenone can reverse the abnormal decrease in hormones and neurosteroids caused by PTSD after spontaneous abortion, particularly the abnormal decrease in serotonin and tetrahydroprogesterone.

The subject matter of the invention is an imidazole-indole derivative of Formula (I): wherein R1 and R2 represent, independently of each other, a hydrogen atom, a halogen atom, a hydroxy group, a substituted or unsubstituted C1-C3 alkoxy group, a substituted or unsubstituted C1-C4 alkyl group, a C1-C3 alkylsulfonyl group, an amide group or a halo-C1-C3 alkylsulfanyl group, or R1 and R2 together form a C1-C3 alkylenedioxy group, or its pharmaceutically acceptable salt. The subject matter of the invention is also a pharmaceutical composition comprising an imidazole-indole derivative of Formula (I) or its pharmaceutically acceptable salt as an active substance. The subject matter of the invention is an imidazole-indole derivative of Formula (I) or its pharmaceutically acceptable salt or a pharmaceutical composition comprising an imidazole- indole derivative of Formula (I) or its pharmaceutically acceptable salt, for use as a 5-HT7 serotonin receptor agonist or for use as a medicine, in particular in the treatment and / or prevention of a disease or disorder in which 5-HT7 serotonin receptor is involved. Moreover, the subject matter of the invention is a method for the treatment or prevention of a disease or disorder in which 5-HT7 serotonin receptor is involved in a subject. The subject matter of the invention is an intermediate product of Formula (II): wherein R1 and R2 substituents are as defined above for the Formula (I).

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a serotonin receptor, such as serotonin receptor 5HT1a, 5HT1b, 5HT1d, 5HT1e, 5HT1f, 5HT2a, 5HT2b, 5HT2c, 5HT3, 5HT4, 5HT6, or 5HT7.

The group of inventions relates to medicine, pharmacology, namely to psychiatry and can be used for effective and safe treatment of mental disorders associated with dysfunction of dopamine and serotonin (5-hydroxytryptamine) neurotransmitter systems. Pharmaceutical compositions containing halogenated clozapine, in an amount effective as selective antagonists of D4 and 5NT2A receptors, and at least one pharmaceutically acceptable carrier, as well as their use and methods of treatment are offered for this purpose. The inventions make it possible to create a new drug with a well-balanced receptor profile, the intake of which will allow to treat mental disorders in an effective way without causing side effects associated with exposure to receptors that are not involved in the pathology of a mental disorder.

According to a first aspect, the invention relates to a pharmaceutical composition prepared for oral administration for the treatment of obesity, comprising an active ingredient which inhibits serine palmitoyltransferase (EC 2.1.3.50). Another aspect of the invention relates to the use of myriocin for the treatment of obesity.

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and n are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental health disease or disorder.

The application discloses a method for differentiating stem cells into caudal serotonergic neurons, a complete culture medium and application. Specifically, a new culture medium is formed by adding small molecule compounds, so that human pluripotent stem cells are gradually induced to obtain hindbrain neural stem cells, ventral hindbrain caudal neural stem cells, serotonergic precursor cells and caudal serotonergic neurons of the hindbrain. The culture method is simple, and can efficiently obtain mature serotonergic neurons of specific regions, thereby providing an effective cell model for research on diseases related to the serotonergic system.

The present invention relates to serotonin 5-HT 2A Antagonists at receptors and serotonin 5-HT 1A The present invention relates to heteroaromatic compounds of formula (I), or isotopic forms, stereoisomers, or pharmaceutically acceptable salts thereof, as agonists at receptors. The present invention also describes methods for making such compounds, pharmaceutical compositions containing such compounds, and their use in treating CNS disorders. JPEG2025530734000067.jpg23170

The present invention is embodied by a composition capable of chaperoning a typically non-orally available therapeutic or diagnostic agent through the environment of the digestive tract such that the therapeutic or diagnostic agent is bioavailable. The composition may or may not be targeted to specific cellular receptors, such as hepatocytes. Therapeutic agents include, but are not limited to, insulin, calcitonin, serotonin, and other proteins. Targeting is accomplished with biotin or metal based targeting agents.

The purpose of the present disclosure is to provide a novel plant environmental stress alleviator, a plant growth promoter, and a plant DNA repair promoter that have an excellent effect of alleviating environmental stresses such as high temperatures.　The present disclosure provides a plant environmental stress alleviator, a plant growth promoter, and a plant DNA repair promoter containing: one or more neurotransmitters selected from choline esters, catecholamines, serotonin, and amino acids, and / or one or more acetylcholinesterase inhibitors selected from polyphenols, flavonoids, and organic acids, or a plant extract containing said inhibitors; and calcium ions. The present disclosure also provides a method for producing the aforementioned agents.

Provided herein are pharmaceutical compositions, kits comprising pharmaceutical compositions, methods of treating disease, and methods of making compositions. The pharmaceutical compositions described herein are powdery pharmaceutical compositions, which can contain encapsulated pharmaceutical agents, such as serotonin receptor agonists. The powdery pharmaceutical compositions may be administered by an inhaler device described herein.

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a serotonin receptor, such as serotonin receptor 5HT1a, 5HT1b, 5HT1d, 5HT1e, 5HT1f, 5HT2a, 5HT2b, 5HT2c, 5HT3, 5HT4, 5HT6, or 5HT7.